|
WO2001083740A2
(en)
|
2000-05-04 |
2001-11-08 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
EP1629105B1
(en)
|
2003-04-29 |
2010-09-01 |
AVI BioPharma, Inc. |
Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
US20050171044A1
(en)
*
|
2003-12-24 |
2005-08-04 |
Stein David A. |
Oligonucleotide compound and method for treating nidovirus infections
|
|
US20050234002A1
(en)
*
|
2004-01-23 |
2005-10-20 |
Mourich Dan V |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
|
CA2571593C
(en)
|
2004-07-02 |
2015-04-21 |
Avi Biopharma, Inc. |
Antisense antibacterial method and compound
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
US7524829B2
(en)
*
|
2004-11-01 |
2009-04-28 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20070265215A1
(en)
*
|
2006-05-11 |
2007-11-15 |
Iversen Patrick L |
Antisense restenosis composition and method
|
|
AU2015200600B2
(en)
*
|
2007-06-29 |
2017-04-20 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
WO2009005793A2
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
EP2181983A4
(en)
*
|
2007-07-25 |
2013-01-02 |
Ajinomoto Kk |
METHOD FOR THE SELECTIVE REMOVAL OF A DIBENZOFULVENE DERIVATIVE
|
|
US8076476B2
(en)
*
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
DK2207779T3
(da)
*
|
2007-11-15 |
2014-07-14 |
Sarepta Therapeutics Inc |
Fremgangsmåde til syntese af morpholinooligomerer
|
|
US8299206B2
(en)
*
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
|
AU2008345033B2
(en)
*
|
2007-12-28 |
2014-04-03 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
US8592386B2
(en)
*
|
2008-12-17 |
2013-11-26 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
CA2764158A1
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
WO2011018798A2
(en)
*
|
2009-08-14 |
2011-02-17 |
Indian Association For The Cultivation Of Science |
Morpholino-based antisense agent
|
|
WO2011026139A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Gen-Probe Incorporated |
Dengue virus assay
|
|
BR122023023194A2
(pt)
|
2009-11-12 |
2023-12-26 |
The University Of Western Australia |
Oligonucleotídeo antissentido, composição e respectivo uso
|
|
JP5991922B2
(ja)
|
2009-11-13 |
2016-09-14 |
サレプタ セラピューティクス， インコーポレイテッド |
アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
|
|
EP3214174B1
(en)
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
|
|
EP2545173A2
(en)
|
2010-03-12 |
2013-01-16 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
ES2816898T3
(es)
*
|
2010-05-13 |
2021-04-06 |
Sarepta Therapeutics Inc |
Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
|
|
KR102182663B1
(ko)
*
|
2010-05-28 |
2020-11-25 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
AU2013202731B2
(en)
*
|
2010-05-28 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
|
NZ605420A
(en)
|
2010-07-06 |
2015-02-27 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
TWI541024B
(zh)
*
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
US10017763B2
(en)
|
2010-09-03 |
2018-07-10 |
Sarepta Therapeutics, Inc. |
dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
|
|
DK2623507T3
(da)
*
|
2010-09-30 |
2017-01-02 |
Nippon Shinyaku Co Ltd |
Morpholinonukleinsyrederivat
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
WO2012100156A1
(en)
|
2011-01-20 |
2012-07-26 |
Hercules Incorporated |
Enhanced dry strength and drainage performance by combining glyoxalated acrylamide-containing polymers with cationic aqueous dispersion polymers
|
|
IL273838B
(en)
|
2011-05-05 |
2022-09-01 |
Sarepta Therapeutics Inc |
Peptide and oligonucleotide conjugates, preparations containing them and their uses
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
EP2732035A2
(en)
|
2011-07-15 |
2014-05-21 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
JP2015500204A
(ja)
*
|
2011-11-18 |
2015-01-05 |
サレプタ セラピューティクス， インコーポレイテッド |
機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
|
|
WO2013082548A1
(en)
|
2011-11-30 |
2013-06-06 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
|
AU2012345638C1
(en)
*
|
2011-11-30 |
2018-10-18 |
Sarepta Therapeutics, Inc. |
Induced exon inclusion in spinal muscle atrophy
|
|
WO2013086441A2
(en)
|
2011-12-08 |
2013-06-13 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human lmna
|
|
ES2886147T3
(es)
|
2011-12-22 |
2021-12-16 |
Interna Tech B V |
MiARN para el tratamiento del cáncer de cabeza y de cuello
|
|
JP6542662B2
(ja)
|
2012-03-20 |
2019-07-10 |
サレプタ セラピューティクス， インコーポレイテッド |
オリゴヌクレオチドアナログのボロン酸結合体
|
|
KR102240217B1
(ko)
|
2012-09-25 |
2021-04-14 |
젠자임 코포레이션 |
근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
|
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
|
JP2016502858A
(ja)
|
2012-12-20 |
2016-02-01 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィを処置するための改善されたエキソンスキッピング組成物
|
|
CN103060325B
(zh)
*
|
2013-01-14 |
2015-01-07 |
韩健宝 |
抗猪流行性腹泻病毒pedv的反义核酸及肽核酸pna
|
|
HRP20190382T1
(hr)
|
2013-03-14 |
2019-04-19 |
Sarepta Therapeutics, Inc. |
Pripravci koji preskaču ekson za liječenje mišićne distrofije
|
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
|
NZ631289A
(en)
|
2013-03-15 |
2017-08-25 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
KR102275504B1
(ko)
|
2013-09-05 |
2021-07-09 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
|
|
WO2015036451A1
(en)
|
2013-09-11 |
2015-03-19 |
Synthena Ag |
Nucleic acids and methods for the treatment of pompe disease
|
|
EP3146050B1
(en)
|
2014-05-23 |
2020-08-12 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
JP6673211B2
(ja)
*
|
2014-10-14 |
2020-03-25 |
味の素株式会社 |
モルフォリノオリゴヌクレオチドの製造方法
|
|
MA41795A
(fr)
*
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US10849917B2
(en)
|
2015-06-01 |
2020-12-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type VII collagen
|
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
AU2016317667A1
(en)
*
|
2015-08-28 |
2018-03-22 |
Sarepta Therapeutics, Inc. |
Modified antisense oligomers for exon inclusion in spinal muscular atrophy
|
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
MY200252A
(en)
|
2016-04-18 |
2023-12-16 |
Sarepta Therapeutics Inc |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
WO2017190041A1
(en)
|
2016-04-29 |
2017-11-02 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human lmna
|
|
SG10202101830WA
(en)
*
|
2016-05-24 |
2021-04-29 |
Sarepta Therapeutics Inc |
Processes for preparing oligomers
|
|
WO2018057430A1
(en)
|
2016-09-20 |
2018-03-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
|
|
LT3554553T
(lt)
|
2016-12-19 |
2022-08-25 |
Sarepta Therapeutics, Inc. |
Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
|
|
CN110381980A
(zh)
|
2017-01-06 |
2019-10-25 |
艾维迪提生物科学有限责任公司 |
核酸-多肽组合物以及诱导外显子跳读的方法
|
|
WO2018162931A1
(en)
*
|
2017-03-10 |
2018-09-13 |
Ucl Business Plc |
Method relating to myostatin pathway inhibition
|
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
MA49986A
(fr)
|
2017-09-25 |
2020-07-01 |
Massachusetts Inst Technology |
Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
|
|
US11110180B2
(en)
|
2017-10-04 |
2021-09-07 |
Avidity Biosciences Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
TW202423453A
(zh)
*
|
2017-10-17 |
2024-06-16 |
美商薩羅塔治療公司 |
用於反義遞送之細胞穿透肽
|
|
EP3700537A4
(en)
*
|
2017-10-17 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
BICYCLIC PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
|
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
|
EP3704250A1
(en)
|
2017-11-03 |
2020-09-09 |
InteRNA Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
WO2019155094A1
(en)
|
2018-02-12 |
2019-08-15 |
Interna Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
|
TW202002990A
(zh)
*
|
2018-03-16 |
2020-01-16 |
美商薩羅塔治療公司 |
用於反義遞送之嵌合肽
|
|
KR102898787B1
(ko)
*
|
2018-05-10 |
2025-12-11 |
니뽄 신야쿠 가부시키가이샤 |
올리고 핵산 화합물의 제조 방법
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
US20220098578A1
(en)
|
2019-01-31 |
2022-03-31 |
Bar Ilan University |
Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
|
|
CA3137715A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
CA3142283A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
CA3165961A1
(en)
|
2019-12-26 |
2021-07-01 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid that induces skipping of exon 50
|
|
AU2021226089A1
(en)
|
2020-02-28 |
2022-09-15 |
National Center Of Neurology And Psychiatry |
Antisense nucleic acid inducing skipping of exon 51
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
BR112022022889A2
(pt)
|
2020-05-11 |
2023-04-04 |
Stoke Therapeutics Inc |
Oligômeros antissentido de opa1 para tratamento de condições e doenças
|
|
CN111575409B
(zh)
*
|
2020-05-23 |
2023-04-18 |
黑龙江八一农垦大学 |
基于整合素配体识别肽抑制猪流行性腹泻病毒感染的研究方法
|
|
CA3202708A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
|
JPWO2022230974A1
(enExample)
*
|
2021-04-28 |
2022-11-03 |
|
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
AU2022298028A1
(en)
|
2021-06-23 |
2023-12-21 |
National Center Of Neurology And Psychiatry |
Combination of antisense oligomers
|
|
JPWO2023282346A1
(enExample)
|
2021-07-08 |
2023-01-12 |
|
|
|
TW202308664A
(zh)
|
2021-07-08 |
2023-03-01 |
日商日本新藥股份有限公司 |
腎毒性減輕劑
|
|
EP4368186A4
(en)
|
2021-07-08 |
2025-06-25 |
Nippon Shinyaku Co., Ltd. |
NEPHROTOXICITY REDUCING AGENT
|
|
US20250011777A1
(en)
|
2021-09-03 |
2025-01-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
JP2024537711A
(ja)
|
2021-09-30 |
2024-10-16 |
サレプタ セラピューティクス， インコーポレイテッド |
１つ以上の脱塩基ユニットを有するアンチセンスオリゴヌクレオチド
|
|
WO2023070086A1
(en)
|
2021-10-22 |
2023-04-27 |
Sarepta Therapeutics, Inc. |
Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
WO2023205451A1
(en)
|
2022-04-22 |
2023-10-26 |
Entrada Therapeutics, Inc. |
Cyclic peptides for delivering therapeutics
|
|
JP2025533454A
(ja)
|
2022-09-21 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
WO2024208249A1
(zh)
|
2023-04-06 |
2024-10-10 |
上海舶望制药有限公司 |
5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸
|
|
TW202442246A
(zh)
|
2023-04-27 |
2024-11-01 |
美商薩羅塔治療公司 |
用於治療慢性腎病之反義寡聚物
|
|
WO2025030099A1
(en)
|
2023-08-02 |
2025-02-06 |
Sarepta Therapeutics, Inc. |
Non-canonical cell-penetrating peptides for antisense oligomer delivery
|
|
AU2024362420A1
(en)
|
2023-10-18 |
2026-04-23 |
Murdoch University |
Antisense oligomers for treatment of centronuclear myopathies
|
|
CN120058705A
(zh)
*
|
2025-04-29 |
2025-05-30 |
苏州诺维康生物科技有限公司 |
一种医药中间体PMO-G(N2-iBu)的合成方法
|